Litigation Details for Novartis AG v. Roxane Laboratories, Inc. (S.D. Ohio 2015)
✉ Email this page to a colleague
Novartis AG v. Roxane Laboratories, Inc. (S.D. Ohio 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-10-13 |
| Court | District Court, S.D. Ohio | Date Terminated | 2015-12-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Edmund A. Sargus Jr. |
| Jury Demand | None | Referred To | Terrence Peter Kemp |
| Parties | ROXANE LABORATORIES, INC. | ||
| Patents | 6,894,051; RE43,932 | ||
| Attorneys | Thomas Louis Rosenberg | ||
| Firms | Roetzel & Andress | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis AG v. Roxane Laboratories, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Novartis AG v. Roxane Laboratories, Inc. (S.D. Ohio 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-10-13 | 1 | THE PATENTS IN SUIT 18. United States Patent No. 6,894,051 (the “’051 Patent”) duly …the ’051 Patent. 20. United States Reissue Patent No. RE43,932 (the “RE932 Patent”) duly …PAGEID #: 6 Patent, would constitute infringement of the ’051 Patent and the RE932 Patent under 35 U.S.C…date on which last-expiring patent of the ’051 Patent and the RE932 Patent expires, including any associated… 1. This is an action for patent infringement arising under the patent laws of the United States, | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
